2015
DOI: 10.1080/21645515.2015.1008877
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
21
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 19 publications
(23 citation statements)
references
References 50 publications
2
21
0
Order By: Relevance
“…Therefore, it will be important to further evaluate the immunogenicity of the 9vHPV vaccine in these regions, especially given the prevalence of HIV infection or other co-infections and malnutrition in these regions which may impact immune response to the vaccine. Of note, studies of the qHPV vaccine in sub-Saharan Africa, India, and Vietnam, and a study in HIV-infected children demonstrated robust immunogenicity in these populations [36] , [37] , [38] , [39] . Given that the 9vHPV vaccine and qHPV vaccine have comparable immunogenicity profiles [10] , [11] , [12] , similar results are expected with the 9vHPV vaccine.…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, it will be important to further evaluate the immunogenicity of the 9vHPV vaccine in these regions, especially given the prevalence of HIV infection or other co-infections and malnutrition in these regions which may impact immune response to the vaccine. Of note, studies of the qHPV vaccine in sub-Saharan Africa, India, and Vietnam, and a study in HIV-infected children demonstrated robust immunogenicity in these populations [36] , [37] , [38] , [39] . Given that the 9vHPV vaccine and qHPV vaccine have comparable immunogenicity profiles [10] , [11] , [12] , similar results are expected with the 9vHPV vaccine.…”
Section: Discussionmentioning
confidence: 99%
“…1). After excluding duplicates, we ultimately included 29 unique studies described in 35 publications in our qualitative and quantitative analysis (Kim 2010 [19], Harper 2006 [20], Kang 2008 [21], Reisinger 2007 [22], Levin 2010 [23], Giuliano 2011 [24], Muñoz 2009 [25] (including Castellsague 2011 [26]), Villa 2006 [27] (including Villa 2005 [28]), Rivera Medina 2010 [29], Vesikari 2015 [30], Konno 2010 [31], Lehtinen 2016 [32], Moreira Jr 2011 [33], Salif Sow 2013 [34], Wheeler 2008 [35], Herrero 2013 [36] (including Beachler 2016 [37], Hildesheim 2014 [38] and Herrero 2011 [39]), Lazcano-Ponce 2009 [40], Kim 2011 [41], Mugo 2015 [42], Wheeler 2016 [43], Zhu 2014 [44], Olsson 2007 [45], Apter 2015 [46] (including Szarewski 2012 [47] and Palmroth 2012 [48]), Toft 2014 [49], Einstein 2014 [50], Schmeink 2011 [51], Konno 2014 [52], Naud 2014 [53], Lim 2014 [54]).
Fig.
…”
Section: Resultsmentioning
confidence: 99%
“…One study [ 42 ] had insufficient information on discontinued data. The risks of bias due to inadequate random sequence generation and inadequate allocation concealment were judged to be ‘unclear’ in seven studies [ 26 , 29 31 , 35 , 38 ] and four studies [ 26 , 33 , 38 ], respectively.
Fig.
…”
Section: Resultsmentioning
confidence: 99%
“… Solicited local symptoms We analyzed nine placebo-controlled studies (four 2vHPV vaccine [ 27 , 31 , 43 , 44 ] and five 4vHPV vaccine studies [ 30 , 38 , 39 , 42 , 46 ]) for the primary safety outcome. A meta-analysis showed a significantly higher incidence of any solicited local symptom in the pooled HPV vaccine (2vHPV and 4vHPV) group compared to the placebo group (overall RR: 1.20, 95% CI: 1.13 to 1.27) (Fig.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation